Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455383) titled 'A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1' on March 3.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Alkermes, Inc.

Condition: Narcolepsy Type 1

Intervention: Drug: ALKS 2680 Dose 1 Drug: ALKS 2680 Dose 2

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: March 2026

Target Sample Size: 150

To know more, visit https://clinicaltrials.gov/study/NCT07455383

Published by ...